Compare AMETEK, Inc. (AME) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs BIO-TECHNE Corp — how do they compare? AMETEK, Inc. trades at $232.13 (market cap $53.63B), while BIO-TECHNE Corp trades at $71.35 (market cap $11.11B). The key difference: AMETEK, Inc. is far larger — about 4.8× BIO-TECHNE Corp's market cap, and AMETEK, Inc. pays the higher dividend (0.58%). Which is the better fit depends on your goals.
| AME | TECH | |
|---|---|---|
Market Cap | $53.63B | $11.11B |
Sector | Industrials | Health |
52-Week High | $241.94 | $71.38 |
52-Week Low | $176.44 | $43.31 |
Enterprise Value | $55.33B | $11.19B |
Dividend Yield | 0.58% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AME trades at $232.1, down 0.8% on the day, with a bullish technical signal and strong earnings beat history. Recent acquisitions in aerospace and defense, like First Aviation Services and the Indicor Instrumentation deal valued at $5 billion, expand its industrial tech portfolio. The company shows consistent revenue growth, reaching $7.4 billion in 2025, and maintains robust profitability with a net income margin of 20.11%.
Outlook is positive with analyst consensus at Buy and a $260 price target, though high valuation ratios like a P/E of 35.34 pose risks. Key opportunities include exposure to 3D printing and quantum computing trends, while risks involve integration of large acquisitions and market volatility.
Bio-Techne Corporation (TECH) trades at $71.30, showing modest daily gains of 0.21%. The stock is positioned near its 52-week high following Merck KGaA's $73 per share acquisition offer announced June 25, 2026. Technical indicators show bullish momentum with strong moving average support, while fundamentals reveal elevated valuation metrics (P/E 101.84) despite recent earnings volatility. The company maintains solid gross margins of 64.96% but has seen net income margin compression from 25.09% in 2023 to 6.01% in 2025.
The acquisition premium provides near-term price support, but shareholder litigation risks emerge regarding deal fairness. Long-term investors face valuation concerns amid declining profitability trends. Analyst consensus is evenly split between Buy and Hold ratings with a $67.75 price target below current levels, suggesting limited upside beyond the acquisition price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
